Innovent Biologics stock | Price, analyst rating, price target & growth

Innovent Biologics

SEHK:1801

HK$ 85,50

+ HK$6,10 (7,68%)

85,50 HK$

+HK$6,10 (7,68%)

End-of-day quote: 03/27/2026

Innovent Biologics Stock Value

Analysts currently give SEHK:1801 a rating of Buy.

Buy

Innovent Biologics Company Info

EPS Growth 5Y

26,05%

Market Cap

HK$148,36 B

Long-Term Debt

HK$2,21 B

Annual earnings

N/A

Dividend

HK$0,00

Dividend Yield

0,00%

Founded

2011

Industry

Health Care

Country

China

Website

Innovent Biologics

ISIN Number

KYG4818G1010

Website

http://www.innoventbio.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

HK$114,78

34.25%

Last Update: 03/29/2026

Analysts: 26

Highest Price Target HK$136,26

Average Price Target HK$114,78

Lowest Price Target HK$81,15

In the last five quarters, Innovent Biologics’s Price Target has risen from HK$26,38 to HK$50,60 - a 91,81% increase. Nineteen analysts predict that Innovent Biologics’s share price will increase in the coming year, reaching HK$114,78. This would represent an increase of 34,25%.

Top growth stocks in the health care sector (5Y.)

What does Innovent Biologics do?

Innovent Biologics, Inc. is a biopharmaceutical company committed to developing and commercializing high-quality innovative therapeutics that are affordable to ordinary people. The company has built a fully integrated multi-functional biopharmaceutical platform consisting of research, chemistry, manufacturing, and clinical development capabilities. It has developed a pipeline covering a variety of novel and validated therapeutic targets and drug modalities, including monoclonal antibodies, multi-specific antibodies, cell engagers, antibody-drug conjugates (ADCs), immuno-cytokines, cell therapies, and small molecules. The pipeline spans multiple major therapeutic areas including oncology, cardiovascular and metabolic diseases, autoimmune disorders, and ophthalmology, with significant clinical and commercial potential as both monotherapies and combination therapies to address unmet medical needs.

Business Segments

The company operates through several critical segments, focusing on the discovery, development, manufacturing, and commercialization of innovative biologics. Its pipeline demonstrates a broad spectrum of therapeutic applications, with special emphasis on oncology, where the majority of its pipeline assets reside. The company employs a strategic approach to R&D leading to discoveries that not only target well-established cancer pathways but also explore novel therapeutic avenues to combat a range of diseases effectively.

In the field of oncology, the company concentrates on creating biologics that can target specific cancer types, such as non-small cell lung cancer (NSCLC), gastric cancer, glioblastoma, and classic Hodgkin lymphoma, among others. The significance of this segment rests on the increasing global prevalence of cancer and the pressing need for innovative therapies that provide better patient outcomes.

The company's non-oncology pipelines focus on various therapeutic areas, including autoimmune disorders and metabolic diseases, reflecting a balanced investment in broadening the treatment capacities beyond oncology. This diversification mitigates risks and prepares the company to respond to shifts in market demands and emerging therapeutic challenges.

Business Strategy

The company’s strategic vision is rooted in sustainability, innovation, and a commitment to enhancing healthcare access worldwide. The company endeavours to establish itself as a premier global biopharmaceutical entity. The company’s strategies are centred around leveraging strategic partnerships, enhancing its R&D capabilities, and ensuring compliance with global regulatory standards to facilitate the smooth introduction of innovative therapeutics in various markets.

By engaging in collaborations with key global pharmaceutical players and research institutions, the company increases its capacity for innovation while minimizing the risks associated with drug development. It focuses on expanding its therapeutic reach through continuous innovation and the exploration of new drug modalities. This involves not only the refinement of existing treatments but also the exploration of novel therapeutic targets in response to evolving medical needs. Additionally, the company aims to enhance operational efficiencies through adopting cutting-edge technologies in its manufacturing processes.

Products and Services

The company offers a diverse range of products primarily in the biopharmaceutical arena, focusing on innovative therapeutics to treat various diseases. The company has developed monoclonal antibodies, bispecific antibodies, cell therapies, and small molecules, which address critical therapeutic areas. The oncology therapeutic candidates are particularly noteworthy, with several products already approved and marketed.

Among its flagship products are monoclonal antibody therapies targeting oncogenic drivers and immune modulation, including drugs like TYVYT® (sintilimab injection), which serves as a PD-1 inhibitor for treating various cancers. Similarly, BYVASDA® (bevacizumab injection) and HALPRYZA® (rituximab injection) have also established their presence in the oncology treatment landscape.

Geographical Markets Served

The company primarily serves the Greater China market, including Mainland China, Hong Kong, Taiwan, and Macau, but is also establishing a foothold in global markets through strategic collaborations and partnerships.

Customers

The company serves an extensive range of customers, including healthcare providers, hospitals, oncology clinics, and pharmaceutical distributors. The company has built relationships with several key stakeholders, including governmental health organizations and private healthcare institutions to facilitate the broader adoption of its therapies. Through these multiple customer channels, the company strives to enhance patient access to its innovative products.

Marketing/Distribution Channels

The company employs a multi-faceted marketing and distribution strategy to reach its customers effectively. The company incorporates both direct sales and strategic partnerships in its approach, allowing it to leverage established distribution networks and expand its market presence. By engaging in educational marketing campaigns aimed at healthcare professionals, the company enhances awareness and understanding of its products while driving demand.

The company also utilizes digital platforms to reach broader audiences and improve access to information regarding its innovative therapies. Collaborations with distributors and healthcare providers ensure more extensive market penetration, promoting enhanced patient access to essential therapeutics.

Regulations

The company adheres to stringent regulatory standards applicable to drug development, clinical trials, manufacturing, and marketing of its products. Compliance with the National Medical Products Administration (NMPA) regulations in China and other relevant international guidelines is crucial for the company.

History

Innovent Biologics, Inc. was founded in 2011. The company was incorporated in 2011.

Innovent Biologics Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Biopharmaceutical Revenues:** 100% (2025) **TOP 3 Markets:** 1. **China:** approx. 70% 2. **USA:** approx. 15% 3. **Europe:** approx. 10% Innovent Biologics, Inc. generates its revenues entirely from the biopharmaceutical industry. The company mainly focuses on the development and commercializat...

At which locations are the company’s products manufactured?

**Production sites of Innovent Biologics, Inc.:** 1. **Suzhou, China** 2. **Hangzhou, China** Innovent Biologics, Inc. mainly produces its biopharmaceutical products in China. The main production facility is located in Suzhou, where the company operates a state-of-the-art plant specialized in the...

What strategy does Innovent Biologics pursue for future growth?

**Focus on R&D Investments:** 30% of revenue (2024) **Expansion of Product Portfolio:** 5 new products in the pipeline (2025) **International Expansion:** Entry into 3 new markets (2025) Innovent Biologics, Inc. places a strong emphasis on research and development by investing a significant...

Which raw materials are imported and from which countries?

**Main raw materials:** Biopharmaceutical active ingredients, cell cultures, reagents **Countries of origin:** USA, Germany, China Innovent Biologics, Inc. is a biopharmaceutical company specializing in the development and production of medications. For the production of its biopharmaceutical prod...

How strong is the company’s competitive advantage?

**Market Share in China:** 10% in the Biopharma Sector (2024) **R&D Investments:** 20% of Revenue (2024) **Patent Portfolio:** Over 50 Active Patents (2024) Innovent Biologics, Inc. has established itself in recent years as one of the leading players in the Chinese biopharma sector. With a...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 68% (2025, estimated) **Insider Buys/Sells:** No significant changes (2025, estimated) The institutional investor share in Innovent Biologics, Inc. is approximately 68%. This indicates a high level of trust from institutional investors in the company, which is ofte...

What percentage market share does Innovent Biologics have?

**Market share of Innovent Biologics:** 4.5% (estimated, 2025) **Top competitors and their market shares:** 1. **Roche Holding AG:** 12.0% 2. **Novartis AG:** 10.5% 3. **AstraZeneca PLC:** 9.0% 4. **Bristol-Myers Squibb:** 8.0% 5. **Pfizer Inc.:** 7.5% 6. **Merck & Co., Inc.:** 7.0% 7. **Sanofi...

Is Innovent Biologics stock currently a good investment?

**Revenue Growth:** 25% (2024) **Research and Development Expenses:** 30% of revenue (2024) **Market Share in China:** 15% in the Oncology sector (2024) Innovent Biologics, Inc. achieved an impressive revenue growth of 25% in 2024, attributed to the successful launch of new drugs and expansion into...

Does Innovent Biologics pay a dividend – and how reliable is the payout?

**Dividend payment:** No dividend (2025) Innovent Biologics, Inc. has not paid any dividends so far. The company is strongly focused on research and development in the field of biotechnology, which typically involves high investments. In the biotechnology industry, it is not uncommon for companies...

New support ticket

Explore

Innovent Biologics Stock Value

Innovent Biologics Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Innovent Biologics do?

Innovent Biologics Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Innovent Biologics Stock Value

Innovent Biologics Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Innovent Biologics do?

Innovent Biologics Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.